The role of peroxisome proliferator-activated receptor γ in bladder cancer in relation to angiogenesis and progression

Laura Possati , Romina Rocchetti , Simona Talevi , Valerio Beatrici , Chiara Margiotta , Luigi Ferrante , Roberta Calza , David Sagrini , Albertino Ferri
{"title":"The role of peroxisome proliferator-activated receptor γ in bladder cancer in relation to angiogenesis and progression","authors":"Laura Possati ,&nbsp;Romina Rocchetti ,&nbsp;Simona Talevi ,&nbsp;Valerio Beatrici ,&nbsp;Chiara Margiotta ,&nbsp;Luigi Ferrante ,&nbsp;Roberta Calza ,&nbsp;David Sagrini ,&nbsp;Albertino Ferri","doi":"10.1016/S0306-3623(01)00116-1","DOIUrl":null,"url":null,"abstract":"<div><p>Peroxisome proliferator-activated receptor γ (PPARγ) immunohistochemical expression was analyzed in 75 human bladder tumor specimens, where the expression of some angiogenic factors, such as vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), platelet-derived endothelial cell growth factor (PDECGF), and tumor progression markers, such as epidermal growth factor receptor (EGFr), p16, mutated p53, and normal pRB, were also analyzed. The results were then compared to the clinical and pathological characteristics of the disease. PPARγ was expressed more significantly in papillary tumors than in solid cancers, and its presence was associated with statistical significance to low incidence of tumor recurrence or progression. This significant association was observed also when PPARγ was expressed in the presence of PDECGF, which resulted, when considered alone, to an angiogenic factor typical of solid cancers and appeared related to poor prognosis. In the presence of bFGF, on the contrary, PPARγ expression no longer resulted to a significant association with low incidence of tumor recurrence or progression, suggesting a possible worsening role of this angiogenic factor, typical of papillary cancers, in its interaction with PPARγ.</p></div>","PeriodicalId":12607,"journal":{"name":"General Pharmacology-the Vascular System","volume":"35 5","pages":"Pages 269-275"},"PeriodicalIF":0.0000,"publicationDate":"2000-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0306-3623(01)00116-1","citationCount":"27","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"General Pharmacology-the Vascular System","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0306362301001161","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 27

Abstract

Peroxisome proliferator-activated receptor γ (PPARγ) immunohistochemical expression was analyzed in 75 human bladder tumor specimens, where the expression of some angiogenic factors, such as vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), platelet-derived endothelial cell growth factor (PDECGF), and tumor progression markers, such as epidermal growth factor receptor (EGFr), p16, mutated p53, and normal pRB, were also analyzed. The results were then compared to the clinical and pathological characteristics of the disease. PPARγ was expressed more significantly in papillary tumors than in solid cancers, and its presence was associated with statistical significance to low incidence of tumor recurrence or progression. This significant association was observed also when PPARγ was expressed in the presence of PDECGF, which resulted, when considered alone, to an angiogenic factor typical of solid cancers and appeared related to poor prognosis. In the presence of bFGF, on the contrary, PPARγ expression no longer resulted to a significant association with low incidence of tumor recurrence or progression, suggesting a possible worsening role of this angiogenic factor, typical of papillary cancers, in its interaction with PPARγ.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
过氧化物酶体增殖物激活受体在膀胱癌血管生成和进展中的作用。
分析了75例人膀胱肿瘤标本中过氧化物酶体增殖物激活受体γ (PPARγ)的免疫组化表达,其中一些血管生成因子,如血管内皮生长因子(VEGF)、碱性成纤维细胞生长因子(bFGF)、血小板来源的内皮细胞生长因子(PDECGF)的表达,以及肿瘤进展标志物,如表皮生长因子受体(EGFr)、p16、突变p53和正常pRB的表达。然后将结果与该疾病的临床和病理特征进行比较。PPARγ在乳头状肿瘤中的表达明显高于实体癌,其存在与肿瘤复发或进展的低发生率有统计学意义。当PPARγ在PDECGF存在下表达时,也观察到这种显著的关联,当单独考虑时,导致实体癌典型的血管生成因子,并且似乎与不良预后有关。相反,在bFGF存在的情况下,PPARγ的表达不再与肿瘤复发或进展的低发生率显著相关,这表明这种典型的乳头状癌血管生成因子在与PPARγ相互作用中的作用可能会恶化。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Analysis of moricizine block of sodium current in isolated guinea-pig atrial myocytes Atrioventricular difference of moricizine block Regulation of chemokine expression in atherosclerosis Homocysteine and arterial disease Experimental mechanisms MS general pharmacology—the vascular system Endothelial dysfunction in atherosclerosis Endothelial cell response to hyperlipemia Activation–dysfunction–injury, the protective role of simvastatin
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1